当前位置: 首页 >> 检索结果
1. Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trial.
作者: Duvuru Geetha.;Christian Pagnoux.;Sebastian E Sattui.;Peter A Merkel.;Maria Weiner.;Juliana Draibe.;Stanislas Faguer.;Sarah Bray.;Rachel E Gurlin.;Monica Balcells-Oliver.;Annette Bruchfeld.;David R Jayne.; .
来源: Rheumatology (Oxford). 2025年64卷6期3863-3871页
To evaluate the efficacy and safety of avacopan in patients aged ≥65 years with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in the phase 3 ADVOCATE trial of avacopan vs a prednisone taper, plus either rituximab or cyclophosphamide.
2. The effect of ixekizumab treatment on MRI sacroiliac joint structural lesions in patients with radiographic axial spondyloarthritis: post-hoc analysis of a 52-week, randomised, placebo-controlled trial with an active reference arm.
作者: Walter P Maksymowych.;Robert G W Lambert.;Rebecca J Bolce.;Natalia Bello.;Baojin Zhu.;Jeffrey R Lisse.;Mikkel Østergaard.
来源: Lancet Rheumatol. 2025年7卷5期e314-e322页
The effect of biological disease-modifying antirheumatic drugs (DMARDs) on sacroiliac joint lesions over 52 weeks in biological DMARD-naive patients with radiographic axial spondyloarthritis is unknown. This post-hoc analysis evaluated the effect of ixekizumab and adalimumab versus placebo on structural lesions in sacroiliac joints assessed by MRI in patients naive to biological DMARDs with radiographic axial spondyloarthritis from the COAST-V study.
3. Baseline synovitis-tenosynovitis is associated with remission in early rheumatoid arthritis, but discordance with disease activity is a changeable state.
作者: Rudresh R Shukla.;Richard J Wakefield.;Pauline Ho.;Ai Lyn Tan.;Paul Emery.;Darren Plant.;Maya H Buch.
来源: Rheumatology (Oxford). 2025年64卷6期3468-3477页
The objectives of this study were to investigate the association between baseline joint-complex inflammation [power Doppler-detected joint synovitis (PDUS) and/or tenosynovitis (PDTS)] and remission in treatment-naïve, new-onset RA patients and to evaluate concordance and discordance states between clinical disease activity and power Doppler US and transition between these states longitudinally.
4. Can treatment expectations or treatment itself in patients with arthralgia suspicious for progression to rheumatoid arthritis improve illness perceptions?
作者: Simonetta R G van Griethuysen.;Quirine A Dumoulin.;Elise van Mulligen.;Annette H M van der Helm-van Mil.
来源: Rheumatology (Oxford). 2025年64卷6期3444-3450页
Negative illness perceptions (IPs) are associated with poorer disease outcomes in rheumatoid arthritis (RA). Unfortunately, IPs are generally stable in established RA. We hypothesized that IPs, especially in the cognitive domain, are modifiable in arthralgia at risk of RA. We aimed to study if receiving DMARD treatment, or the offer of DMARD treatment associates with more positive IPs in patients with clinically suspect arthralgia (CSA).
5. Addition of aerobic physical activity to resistance exercise for hip osteoarthritis (PHOENIX): a randomised comparative effectiveness trial.
作者: Michelle Hall.;Kim Allison.;Gabrielle Knox.;Fiona McManus.;Rana S Hinman.;Kim L Bennell.;Libby Spiers.;Anurika P De Silva.;David M Klyne.;Melanie L Plinsinga.;Ricardo J S Costa.;Nicholas J Murphy.;Wen Wu.;Fiona L Dobson.
来源: Lancet Rheumatol. 2025年7卷5期e343-e354页
Exercise is recommended for hip osteoarthritis, but the most effective programmes for management of symptoms are unknown. We aimed to investigate whether adding aerobic physical activity to resistance exercise would improve hip pain and function more than resistance exercise alone in individuals with hip osteoarthritis.
6. Comparison of the efficacy and safety of methotrexate injection and methotrexate tablets in active RA.
作者: Lin Qiao.;Jiankang Hu.;Daming Ou.;Mixia Liu.;Xiaofei Shi.;Xiaomei Li.;Rui Wu.;Liyun Zhang.;Yuan Liu.;Changhong Xiao.;Zili Fu.;Jin Lin.;Rongsheng Wang.;Dongmei Zhou.;Jing Yu.;JingChun Jin.;Shulin Song.;Lin Tang.;Hongsheng Sun.;Yuanyuan Yin.;Xiaofeng Zeng.
来源: Rheumatology (Oxford). 2025年64卷6期3426-3433页
This study aimed to compare the efficacy and safety of subcutaneous MTX (SC MTX) and oral MTX (OR MTX) in treating Chinese patients with active RA.
7. Predictors of response to intravenous immunoglobulin in patients with dermatomyositis: the ProDERM study.
作者: Christina Charles-Schoeman.;Joachim Schessl.;Zsuzsanna Bata-Csörgő.;Mazen M Dimachkie.;Zoltan Griger.;Sergey Moiseev.;Chester V Oddis.;Elena Schiopu.;Jiri Vencovský.;Elisabeth Clodi.;Todd Levine.;Rohit Aggarwal.
来源: Rheumatology (Oxford). 2025年64卷6期3767-3776页
The phase 3 ProDERM study demonstrated intravenous immunoglobulin (IVIg) was safe and effective in patients with dermatomyositis (DM). This analysis assessed clinical and serological predictors of IVIg response in DM patients from ProDERM.
8. A phase 2 randomized trial of safety and pharmacokinetics of IgPro20 and IgPro10 in patients with diffuse cutaneous systemic sclerosis.
作者: Christopher P Denton.;Otylia Kowal-Bielecka.;Susanna M Proudman.;Marzena Olesińska.;Margitta Worm.;Nicoletta Del Papa.;Marco Matucci-Cerinic.;Jana Radewonuk.;Jeanine Jochems.;Adrian Panaite.;Amgad Shebl.;Anna Krupa.;Yannick Allanore.;Jutta H Hofmann.;Maria J Gasior.
来源: Rheumatology (Oxford). 2025年64卷6期3657-3666页
The primary objective was the safety of s.c. immunoglobulin, IgPro20 (Hizentra, CSL Behring) in adults with dcSSc. Secondary objectives included pharmacokinetics and relative bioavailability of IgPro20, and safety and pharmacokinetics of IVIG, IgPro10 (Privigen, CSL Behring).
9. Faecal microbiota transplantation in patients with systemic sclerosis and lower gastrointestinal tract symptoms in Norway (ReSScue): a phase 2, randomised, double-blind, placebo-controlled trial.
作者: Håvard Fretheim.;Imon Barua.;Gunnstein Bakland.;Alvilde Dhainaut.;Anne-Kristine Halse.;Maylen N Carstens.;Henriette Didriksen.;Øyvind Midtvedt.;Knut E A Lundin.;Lars Aabakken.;Vikas K Sarna.;Hasse K Zaré.;Dinesh Khanna.;Oliver Distler.;Tore Midtvedt.;Espen S Bækkevold.;Inge C Olsen.;Diana Domanska.;Maiju E Pesonen.;Øyvind Molberg.;Anna-Maria Hoffmann-Vold.
来源: Lancet Rheumatol. 2025年7卷5期e323-e332页
Gastrointestinal tract involvement is highly prevalent in systemic sclerosis, with few treatment options. We assessed the efficacy and safety of faecal microbiota transplantation using standardised anaerobic cultivated human intestinal microbiome (ACHIM) as a novel treatment option for patients with systemic sclerosis and symptomatic lower gastrointestinal tract involvement.
10. Teledidactic peer-tutored musculoskeletal ultrasound training for medical students-the TELMUS study.
作者: Ricarda Neubauer.;Florian Recker.;Claus-Juergen Bauer.;Simon Petzinna.;Pantelis Karakostas.;Charlotte Behning.;Valentin Sebastian Schäfer.
来源: Rheumatology (Oxford). 2025年64卷6期3344-3351页
Despite growing interest in musculoskeletal ultrasound (MSUS), training opportunities are often limited due to staff shortages and disbalances of expertise between rural and urban areas. Teledidactic approaches have the potential to expand access to training opportunities. This study aims to compare the effectiveness of teledidactic peer-tutored MSUS training to a conventional approach.
11. Baricitinib in early polymyalgia rheumatica (BACHELOR): a randomised, double-blind, placebo-controlled, parallel-group trial.
作者: Alain Saraux.;Guillermo Carvajal Alegria.;Emmanuelle Dernis.;Christian Roux.;Christophe Richez.;Alice Tison.;Baptiste Quere.;Sandrine Jousse-Joulin.;Dewi Guellec.;Thierry Marhadour.;Patrice Kervarrec.;Divi Cornec.;Catherine Le Henaff.;Sandra Lesven.;Emmanuel Nowak.;Aghiles Souki.;Valérie Devauchelle-Pensec.
来源: Lancet Rheumatol. 2025年7卷4期e233-e242页
Moderate doses of glucocorticoids result in improvements in nearly all patients with polymyalgia rheumatica, but related adverse events are common in older individuals. We aimed to evaluate whether treatment with baricitinib (a Janus kinase 1/2 inhibitor) results in disease control without the use of oral glucocorticoids in people with recent-onset polymyalgia rheumatica.
12. Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies.
作者: Xenofon Baraliakos.;Atul Deodhar.;Désirée van der Heijde.;Filip Van den Bosch.;Marina Magrey.;Walter P Maksymowych.;Tetsuya Tomita.;Huji Xu.;Ute Massow.;Tom Vaux.;Chetan Prajapati.;Myriam Manente.;Alexander Marten.;Lianne S Gensler.
来源: Rheumatology (Oxford). 2025年64卷6期3534-3546页
Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, previously demonstrated efficacy and was well tolerated to 1 year in patients with non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis (axSpA). Here, we report bimekizumab safety and efficacy to 2 years.
13. Blood pressure changes during methotrexate treatment: results from a randomized placebo-controlled trial among patients with cardiovascular risk.
Low-dose MTX (LD-MTX) has been associated with a reduced risk of cardiovascular disease (CVD) among patients with systemic rheumatic diseases but not among the general population. Prior reports suggest that LD-MTX may reduce blood pressure (BP). We studied the effect of LD-MTX on BP.
14. Dermal cellular senescence and EndMT in patients with systemic sclerosis undergoing cyclophosphamide or aHSCT treatment.
作者: Yu-Hsiang Chiu.;Marijke van Dijk.;Roel Goldschmeding.;Jacob M van Laar.;Jeska K de Vries-Bouwstra.;Julia Spierings.
来源: Rheumatology (Oxford). 2025年64卷6期3957-3963页
Cellular senescence and endothelial-to-mesenchymal transition (EndMT) are profibrotic cellular processes involved in systemic sclerosis (SSc), but how they respond to treatment is largely unknown.
15. Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a phase 2, randomized, placebo-controlled study.
作者: Hans-Joachim Anders.;Tak Mao Chan.;Jorge Sanchez-Guerrero.;David Wofsy.;Karen Bensley.;Lilianne Kim.;Kim Hung Lo.;Cathye Shu.;Jie Shao.;Chetan S Karyekar.;Betty Diamond.
来源: Rheumatology (Oxford). 2025年64卷5期2731-2740页
Evaluate the efficacy and safety of guselkumab, an IL-23p19-subunit inhibitor, in a phase 2, multicentre, randomized, double-blind, placebo-controlled study of patients with active LN.
16. Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial.
作者: Anca D Askanase.;David D'Cruz.;Kenneth Kalunian.;Joan T Merrill.;Sandra V Navarra.;Clélia Cahuzac.;Peter Cornelisse.;Mark J Murphy.;Daniel S Strasser.;Luba Trokan.;Ouali Berkani.
来源: Lancet Rheumatol. 2025年7卷1期e21-e32页
Sphingosine-1-phosphate (S1P) is a signalling molecule that has an inhibitory role in atherosclerosis, inflammation, cell proliferation, and immunity. Cenerimod is a selective S1P1 receptor modulator under investigation for the treatment of systemic lupus erythematosus (SLE). We aimed to determine the efficacy, safety, and tolerability of four doses of cenerimod in adults with moderate-to-severe SLE receiving standard of care background therapy.
17. A mobile app to support self-management and remotely monitor disease impact in rheumatoid arthritis: the randomized controlled AEGORA trial.
作者: Michaël Doumen.;Elias De Meyst.;Delphine Bertrand.;Sofia Pazmino.;Marine Piessens.;Johan Joly.;Mieke Devinck.;René Westhovens.;Patrick Verschueren.
来源: Rheumatology (Oxford). 2025年64卷5期2505-2514页
The aim of this work was to determine whether smartphone applications could support the self-management of RA and to investigate engagement and potential negative psychological effects with app-use.
18. Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort.
作者: Yann Nguyen.;Gabriel Baron.;Naima Hamamouche.;Rakiba Belkhir.;Sylvie Miconnet.;Martin Soubrier.;Camille Hostachy.;Pascale Thevenot.;André Basch.;Marie-Elise Truchetet.;Pascal Claudepierre.;Emmanuelle Dernis.;Hubert Marotte.;René-Marc Flipo.;Olivier Brocq.;Jacques Morel.;Bruno Fautrel.;Carine Salliot.;Alain Saraux.;Charles Leske.;Thierry Schaeverbeke.;Philippe Ravaud.;Xavier Mariette.;Adeline Ruyssen-Witrand.;Raphaèle Seror.; .
来源: Rheumatology (Oxford). 2025年64卷5期2496-2504页
The objectives of this study were to evaluate the effectiveness of short message service (SMS) and/or email reminders in improving influenza vaccination coverage rates among RA patients treated with anti-TNF therapies, and to identify factors associated with vaccination.
19. Patient-initiated follow-up supported by asynchronous telemedicine versus usual care in spondyloarthritis (TeleSpA-study): a randomised controlled trial of clinical and cost-effectiveness.
作者: Kasper Hermans.;Casper Webers.;Annelies Boonen.;Harald E Vonkeman.;Astrid van Tubergen.
来源: Lancet Rheumatol. 2024年6卷12期e848-e859页
With rising health-care expenditures and workforce shortages, sustainable alternatives to traditional outpatient follow-up strategies are required to optimise care efficiency. We aimed to investigate the cost-effectiveness and clinical effectiveness of patient-initiated follow-up (PIFU) supported by asynchronous telemedicine for patients with spondyloarthritis compared with usual care in daily practice.
20. Evaluation of proximod, a selective agonist of sphingosine-1-phosphate receptor-1, in healthy volunteers and patients with rheumatoid arthritis: a phase 1, double-blind, randomised, placebo-controlled, ascending dose trial.
作者: Hong Zhang.;Qianqian Li.;Cuiyun Li.;Min Wu.;Hong Chen.;Yang Li.;Feng You.;Yanshi Zhao.;Jing Jin.;Xiaoguang Chen.;Yanhua Ding.
来源: Lancet Rheumatol. 2024年6卷12期e837-e847页
Proximod is a selective agonist of sphingosine-1-phosphate receptor-1 (S1PR1). It acts by redirecting lymphocytes from the circulation to secondary lymph nodes, and is under development as an immunomodulator for rheumatoid arthritis. We aimed to evaluate the safety, pharmacokinetics, and preliminary efficacy of proximod in healthy volunteers and patients with rheumatoid arthritis.
|